Imunon Inc’s 2025 Q4 Earnings Call: FDA Submission Delays, Shifting Trial Timelines, and Enrollment Discrepancies Highlight Contradictions

Date of Call: Mar 31, 2026

Financials Results

• EPS: $6.83 net loss per share (2025), compared to $16.94 net loss per share in 2024

Guidance:

• Patient enrollment goal for the OVATION 3 trial is to reach approximately 80 patients within the next 12 months, with enrollment completion targeted for 2029.
• Cash runway is projected to extend into the second half of 2026 based on current cash, financial activities, and cost-saving initiatives.
• Ongoing efforts to secure financing for the OVATION 3 study with long-term-oriented investors.
• Continued strategic reorganization and cost optimization to focus exclusively on OVATION 3.

Business Commentary:

Strong Momentum in Clinical Trials:

• Imunon's OVATION 3 pivotal phase III study is advancing rapidly, with enrollment well ahead of plan, aiming for approximately 80 patients within the next 12 months and completion in 2029.
• The momentum is driven by the compelling phase II clinical data showing a 14.7-month median overall survival benefit and enthusiasm from the medical community.

Financial Stability and Strategic Focus:

• The company reported cash and cash equivalents of $8.8 million as of December 31, 2025, extending its operating runway into the second half of 2026 through disciplined cash management and cost-saving initiatives.
• This stability is attributed to a multi-pronged financing strategy, including targeted equity raises, ATM usage, and partnership discussions.

Positive Phase II Clinical Data:

• IMNN-001 demonstrated a clinically meaningful 14.7-month median overall survival benefit in the OVATION 2 study, with patients treated with PARP inhibitors showing a 2-year increase in overall survival.
• The positive data has intensified interest from potential partners and investors, supporting the company's strategic goals.

Regulatory Alignment and Path to Approval:

• The FDA has endorsed overall survival as the primary endpoint for the phase III trial, de-risking the path to potential regulatory approval in the U.S. and Europe.
• This alignment is supported by a robust statistical framework and precedent in oncology drug development.

Enthusiasm and Engagement in the Medical Community:

• The positive clinical data has generated significant excitement, with investigators actively approaching Imunon to join the phase III trial, indicating strong support for IMNN-001's potential in ovarian cancer treatment.
• This engagement is fueled by the unprecedented survival benefits shown in the phase II study and the mechanism of action that activates both innate and adaptive immunity.

Sentiment Analysis:

Overall Tone: Positive

• The call highlights 'strong momentum,' 'disciplined execution,' and 'accelerating progress' in the OVATION 3 trial, with enrollment 'well ahead of plan.' Management expresses confidence in the 'unprecedented' phase II data and its ability to 'create value inflection in 2026 and beyond.' The tone is optimistic regarding the potential for IMNN-001 to 'revolutionize the standard of care.'

Q&A:

• Question from Emily Bodnar (H.C. Wainwright): Have you presented the final data from OVATION002 to the FDA, particularly on the PARP inhibitor patient population? Have you received any feedback from the FDA on focusing on this patient population first in your OVATION003 study? Maybe if you could just kind of outline how you’re thinking about upcoming milestones and catalysts for 2026 and any OVATION003 updates that you’re considering for this year.
  Response: The final OS data has not been presented to the FDA. The focus is on replicating the unprecedented overall survival benefit in the entire patient population in the phase III trial. Upcoming catalysts include reporting trial momentum (targeting 80 patients in 12 months), presenting at medical congresses, publishing translational data, and advancing partnership discussions to fund the trial.

• Question from James Molloy (Alliance Global Partners): Could you walk us through what potential cut points for interim looks we might be able to anticipate going forward over the next 12 months?
  Response: The first interim analysis is designed to occur approximately one year after full enrollment, based on simulations, allowing for a potential BLA filing if a significant effect is observed. Subsequent interims are also planned, with careful balancing of type one error rates.

• Question from Jason McCarthy (Maxim Group): Going back to OVATION 2, is there gonna be an opportunity when you continue to mine that data? Will you have anything related to minimal residual disease or any second-look laparotomy looks for MRD, or any more immune data that might be suggestive of T-cell memory or something that’s keeping these patients’ disease kind of in check, and that could be driving these longer-term survivors?
  Response: OVATION 2 does not include MRD or second-look laparotomy data. Additional translational data from OVATION 2, such as peripheral immune responses, will be presented and published. The MRD study is separate and aims to establish predictive markers like circulating tumor DNA.

• Question from Kemp Dolliver (Brookline Capital Markets): Are the savings from the restructuring of any significance that we would see the impact of them in the first half of this year?
  Response: The strategic restructuring is focused on aligning resources and expertise with the sole goal of advancing OVATION 3, not on a specific financial savings number. It ensures the company is focused on its core objective.

• Question from David Gaiero (D. Boral Capital): As resources become available, is the company gonna look to open additional sites in the U.S. or are you looking ex-U.S. to get any international sites open? As far as payments for the phase III trial, I guess I’m just trying to look ahead, you know, how is it being paid for? You know, did you have a bullet payment up front? Is it pay-as-you-go? Like, how is it structured?
  Response: Site activation is currently focused in the U.S., with potential to add sites in Canada or Europe later to accelerate enrollment. Trial payments are structured traditionally with contracts that include startup fees and per-patient treatment fees, utilizing standard of care payment routes where possible.

Contradiction Point 1

FDA Submission Status for Final OS Data from OVATION002

Contradiction on whether final overall survival data has been submitted to the FDA, impacting regulatory timeline expectations.

Emily Bodnar (H.C. Wainwright) - Emily Bodnar (H.C. Wainwright)

2025Q4: The final OS data from OVATION 2 has not been presented to the FDA yet... - Dr. Stacy Lindborg(CSO)

Have you presented the final data from OVATION002 to the FDA? - Emily Bodnar (H.C. Wainwright & Co.)

2025Q3: OVATION 2 overall survival monitoring is expected to wind down by year-end, with final data refresh by end of 2025/early 2026. - Dr. Stacy Lindborg(CSO)

Contradiction Point 2

Interim Analysis Plan for OVATION003

Contradiction on the specific timing for the first interim analysis, affecting trial milestone predictability.

What is James Molloy's role at Alliance Global Partners? - James Molloy (Alliance Global Partners)

2025Q4: The first interim analysis is designed to occur about one year after full enrollment of the trial... - Dr. Stacy Lindborg(CSO)

What potential cut points for interim analyses can we expect over the next 12 months? - David Bautz (Zacks Small-Cap Research)

2025Q3: A positive interim analysis...would lead to a full approval... The trial continues in an all-comers population... The specific thresholds are tied to the trial's statistical design and evolving data. - Stacy Lindborg(CSO)

Contradiction Point 3

Enrollment Pace and Trial Momentum

Statements about enrollment velocity and trial progress conflict between quarters, affecting expectations for trial timeline and resource planning.

"What are the key takeaways from the company's latest earnings report?" - Kemp Dolliver (Brookline Capital Markets)

2025Q4: Enrollment velocity is above the assumed rate of 0.3 patients per site per month, with some sites delivering up to 1 patient per month. The momentum is driven by strong investigator and patient interest... The trial is ahead of plan. - Stacy Lindborg(CEO)

Are the restructuring savings significant and expected in the first half of this year, and is enrollment pace increasing monthly or consistently above forecast? - James Francis Molloy (Alliance Global Partners, Research Division)

2025Q2: On the Avastin trial, the next data set and timing are not controlled by the company. Some preliminary findings are available... - Stacy Lindborg(CEO)

Contradiction Point 4

Trial Payment Structure

Descriptions of how Phase III trial costs are managed differ significantly, impacting financial risk exposure and budget forecasting.

What are the key financial insights or strategic priorities highlighted by David Gaiero of D. Boral Capital? - David Gaiero (D. Boral Capital)

2025Q4: The trial uses a traditional contract structure with individual sites. Payments include startup fees and per-patient treatment fees. The company structures contracts to have standard of care procedures paid through traditional routes, minimizing its financial exposure. - Stacy Lindborg(CEO)

As resources become available, will the company open additional sites in the U.S. or expand internationally, and how is the phase III trial being funded (e.g., bullet payments, pay-as-you-go)? - Emily Claudia Bodnar (H.C. Wainwright & Co, LLC, Research Division)

2025Q2: For OVATION 3, startup costs (including manufacturing) have been incurred in advance, and expenses will be monitored in real-time with enrollments, leading to a stable expense profile. - Stacy Lindborg(CEO)

Contradiction Point 5

Primary Endpoint and Interim Analysis Focus for OVATION 3

Contradiction on whether the initial HRD-positive population analysis is the primary focus, affecting trial design and regulatory strategy.

Emily Bodnar (H.C. Wainwright) - Emily Bodnar (H.C. Wainwright)

2025Q4: The primary goal remains the phase III OVATION 3 trial, building momentum and excitement. - Dr. Stacy Lindborg(CFO)

Have you presented the final data from OVATION002 to the FDA, particularly on the PARP inhibitor patient population, received any feedback on focusing on this population first in OVATION003, and what are the upcoming milestones, catalysts for 2026, and any updates on OVATION003? - Emily Bodnar (H.C. Wainwright)

2025Q1: The statistical analysis plan for Phase III is predicated on analyzing the HRD-positive population first, as this is where the highest treatment effect was observed... - Douglas V. Faller(CEO)